The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.
- A composition comprising (A) a fusion protein comprising (i) a peptide fragment of amino acid of SEQ ID NO: 2 wherein the peptide fragment elicits an immune response to H. influenzae pilin polypeptide or wherein the peptide fragment inhibits H. influenzae cellular adherence and (ii) an immunogenic protein and (B) an adjuvant.
- The composition of claim 1 further comprising a pharmaceutically acceptable carrier.
- A composition comprising (A) a fusion protein comprising (i) a peptide fragment of the amino acid of SEQ ID NO: 2 wherein the peptide fragment comprises amino acids 69-102 of SEQ ID NO:2 wherein the peptide fragment elicits an immune response to H. influenzae pilin polypeptide or wherein the peptide fragment inhibits H. influenzae cellular adherence and (ii) an immunogenic protein and (B) an adjuvant.
- The composition of claim 3 further comprising a pharmaceutically acceptable carrier.
- A composition comprising (A) a fusion protein comprising (i) a peptide fragment of the amino acid of SEQ ID NO: 2 wherein the peptide fragment comprises amino acids 103-137 of SEQ ID NO:2 wherein the peptide fragment elicits an immune response to H. influenzae pilin polypeptide or wherein the peptide fragment inhibits H. influenzae cellular adherence and (ii) an immunogenic protein and (B) an adjuvant.
- The composition of claim 5 further comprising a pharmaceutically acceptable carrier.
- A method for eliciting an immune response to nontypeable H. influenzae comprising administering an immunogenic dose of a fusion protein comprising (i) a peptide fragment of amino acid of SEQ ID NO: 2 wherein the peptide fragment elicits an immune response to H. influenzae pilin polypeptide or wherein the peptide fragment inhibits H. influenzae cellular adherence and (ii) an immunogenic protein.
- A method for eliciting an immune response to nontypeable H. influenzae comprising administering an immunogenic dose of a fusion protein comprising (i) a peptide fragment of the amino acid of SEQ ID NO: 2 wherein the peptide fragment comprises amino acids 69-102 of SEQ ID NO:2 wherein the peptide fragment elicits an immune response to H. influenzae pilin polypeptide or wherein the peptide fragment inhibits H. influenzae cellular adherence and (ii) an immunogenic protein.
- A method for eliciting an immune response to nontypeable H. influenzae comprising administering an immunogenic dose of a fusion protein comprising (i) a peptide fragment of the amino acid of SEQ ID NO: 2 wherein the peptide fragment comprises amino acids 103-137 of SEQ ID NO:2 wherein the peptide fragment elicits an immune response to H. influenzae pilin polypeptide or wherein the peptide fragment inhibits H. influenzae cellular adherence and (ii) an immunogenic protein.
Information currently unavailable.
-
A61K2039/505
Explore more patents:
-
A61K39/00
Explore more patents:
-
A61K39/102
Explore more patents:
-
C07K14/195
Explore more patents:
-
C07K14/285
Explore more patents:
-
C07K16/1242
Explore more patents:
-
C07K2319/00
Explore more patents:
-
C12Q1/689
Explore more patents:
-
Y10S435/851
Explore more patents:
-
A61K39/00
Explore more patents:
-
A61K39/02
Explore more patents:
-
A61K39/102
Explore more patents:
-
A61K45/00
Explore more patents:
-
C07H21/04
Explore more patents:
-
C07K14/195
Explore more patents:
-
C07K14/285
Explore more patents:
-
C12N15/74
Explore more patents:
Document Preview
- Publication: Jan 3, 2017
-
Application:
Mar 7, 2016
US 201615062897 A
-
Priority:
Mar 7, 2016
US 201615062897 A
-
Priority:
Jan 9, 2015
US 201514593401 A
-
Priority:
Feb 13, 2013
US 201313766008 A
-
Priority:
Jan 12, 2011
US 201113005166 A
-
Priority:
Jan 7, 2008
US 97027308 A
-
Priority:
Dec 21, 2004
US 1900504 A
-
Priority:
Dec 23, 2003
US 53229603 P